- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Mycamine (micafungin) / Astellas
Journal: Design, synthesis and biological evaluation of natural product echinocandin derivatives. (Pubmed Central) - Jul 10, 2025 Subsequent pharmacokinetic studies in rats showed significantly higher plasma exposure levels [Cmax, AUC(0-t)] of the optimized compounds than those of Rezafungin. To sum up, SIPI-18333 and SIPI-18334 exhibit superior anti-fungal activity and enhanced bioavailability, which are promising candidates for the next-generation anti-fungal agents and warrant further development.
- |||||||||| Journal: Innovative therapies for treatment of invasive fungal diseases (Pubmed Central) - Jul 1, 2025
Fosmanogepix targets glycosylphosphatidylinositol biosynthesis, while Olorofim, an orotomide, inhibits fungal nucleic acid synthesis, both currently assessed in advanced clinical trials.Immunotherapeutic approaches include immune checkpoint inhibitors to enhance immune response in immunosuppressed individuals and fungal-specific allogeneic CAR-T cell therapy...have been discovered but are not yet seen in clinical trials. Vaccines against distinct fungal antigens as well as pan fungal vaccines to prevent IFD are under development in preclinical stages, notably for Candida spp., Cryptococcus spp., and Aspergillus spp., however, their clinical value is still discussed.In summary, major advances to treat IFD have been observed, but challenges for their establishment in the clinical routine persist.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, voriconazole / Generic mfg.
Journal: Early use of the novel antifungal rezafungin: a case series and literature review. (Pubmed Central) - Jul 1, 2025 Vaccines against distinct fungal antigens as well as pan fungal vaccines to prevent IFD are under development in preclinical stages, notably for Candida spp., Cryptococcus spp., and Aspergillus spp., however, their clinical value is still discussed.In summary, major advances to treat IFD have been observed, but challenges for their establishment in the clinical routine persist. Early use of rezafungin at our centre and in the international literature suggests it is a well-tolerated, convenient and useful addition to the antifungal armamentarium, particularly in the outpatient setting.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Eraxis (anidulafungin) / RaQualia, amphotericin b liposome / Generic mfg.
Review, Journal: Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review. (Pubmed Central) - May 27, 2025 Early and appropriate antifungal treatment, which is associated with better clinical outcomes, is negatively affected by the increased isolation of non-albicans Candida strains that are resistant to the commonly used azoles and echinocandins. Based on the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the different treatment options, liposomal amphotericin B, rezafungin or high doses of anidulafungin appear to be the most appropriate first-line options for complicated IAC in ICUs.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Brexafemme (ibrexafungerp) / SCYNEXIS, GSK
Journal: Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. (Pubmed Central) - May 15, 2025 In conclusion, our in vitro model highlights the antibiofilm activity of novel antifungals against major Candida species, revealing significant differences in efficacy among species. MNGX demonstrated the highest activity, underscoring its potential as a promising candidate for the treatment of biofilm-related infections.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, fluconazole oral / Generic mfg.
Journal: A case of recurrent Candida glabrata fungemia and successful treatment with rezafungin. (Pubmed Central) - May 7, 2025 She had affliction of her prosthetic pulmonic valve with C. glabrata and was treated with the second-generation echinocandin, rezafungin, for six months. This case illustrates the tolerability profile of long-term treatment with rezafungin.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Mycamine (micafungin) / Astellas
Journal: Rezafungin for suppressive therapy of Candida auris in a patient with a left ventricular assist device (LVAD). (Pubmed Central) - May 7, 2025 Though the patient did develop a breakthrough C. auris bloodstream infection while on rezafungin therapy, his infection was well-controlled for a little over 4 months, which prevented any C. auris-related hospital admissions during that time period. This case represents the first example of rezafungin being used for an LVAD-associated C. auris infection.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Journal: Activity of rezafungin against Candida auris. (Pubmed Central) - Apr 30, 2025 Although there is currently a dearth of data on the therapeutic activity of rezafungin against C. auris, it is reasonable that rezafungin may be a viable choice for treating candidemia and invasive candidiasis caused by C. auris. Further clinical investigations are necessary.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Trial completion date, Trial termination, Trial primary completion date: Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age (clinicaltrials.gov) - Apr 7, 2025 P1, N=32, Terminated, Trial completion date: Dec 2027 --> Oct 2024 | Suspended --> Terminated | Trial primary completion date: Mar 2027 --> May 2024; The study had initially anticipated dosing of the first cohort within 4-9 months of activation; however the study faced significant challenges in recruitment. In order to adhere to the previously approved PIP plan, the study could not be redesigned.
- |||||||||| CD388 / Cidara Therap, J&J, Relenza (zanamivir) / GSK, Vaxart
Preclinical, Journal: Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice. (Pubmed Central) - Apr 3, 2025 CD388 improves the antiviral activity of zanamivir, demonstrating potent, universal activity across influenza A and B viruses, including high pathogenicity and neuraminidase inhibitor resistant strains, a low potential for resistance development and potent efficacy in lethal mouse infection models. These results suggest that CD388 has the potential for universal prevention of influenza A and B in healthy and high-risk populations.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Trial completion date: Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults (clinicaltrials.gov) - Apr 2, 2025 P2, N=50, Recruiting, These results suggest that CD388 has the potential for universal prevention of influenza A and B in healthy and high-risk populations. Trial completion date: Dec 2024 --> Aug 2025
- |||||||||| Journal: Antifungal pipeline: New tools for the treatment of mycoses. (Pubmed Central) - Mar 14, 2025
New antifungal agents, such as ibrexafungerp, rezafungin, oteseconazole, and miltefosine, offer novel mechanisms of action along with reduced toxicity...This review provides a comprehensive overview of these new agents and their mechanisms, and explores the challenges and roles of antifungal drugs in LMICs, where the burden of fungal infections is high. Continued research and development are essential to address the rising incidence and resistance of fungal infections globally.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Eraxis (anidulafungin) / RaQualia, Mycamine (micafungin) / Astellas
Review, Journal: Rezafungin in special populations with candidaemia and/or invasive candidiasis. (Pubmed Central) - Mar 6, 2025 Rezafungin appears to be suitable for use in a variety of special populations without the need for dose modifications based on available data, including patients with organ dysfunction or obesity, and elderly and critically ill patients. Further research is needed in populations where rezafungin data are not available including children, people living with HIV, patients receiving ECMO and those with underlying neurological conditions.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Eraxis (anidulafungin) / RaQualia, Mycamine (micafungin) / Astellas
Journal: Activity of Rezafungin Against Echinocandin Non-wild type Candida glabrata Clinical Isolates From a Global Surveillance Program. (Pubmed Central) - Mar 6, 2025 Isolates harboring the FKS2 HS1 S663P alterations were more resistant to echinocandins-3.2% susceptible (anidulafungin) to 35.5% (rezafungin CLSI breakpoint)-when compared with other single alterations. Rezafungin dosing and pharmacokinetic/pharmacodynamic characteristics allow for coverage of higher minimum inhibitory concentration values, making this agent an attractive option for some isolates that carry FKS alterations and still demonstrate rezafungin-susceptible minimum inhibitory concentration values.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Trial initiation date: Rezafungin Prophylaxis in Liver Transplant (clinicaltrials.gov) - Mar 4, 2025 P3, N=385, Not yet recruiting, Rezafungin dosing and pharmacokinetic/pharmacodynamic characteristics allow for coverage of higher minimum inhibitory concentration values, making this agent an attractive option for some isolates that carry FKS alterations and still demonstrate rezafungin-susceptible minimum inhibitory concentration values. Initiation date: Jan 2025 --> Jun 2025
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Review, Journal: Rezafungin: A Review in Invasive Candidiasis. (Pubmed Central) - Feb 6, 2025 Rezafungin was generally well tolerated, with the most common treatment-emergent adverse events being hypokalaemia, pyrexia, diarrhoea and anaemia. Therefore, rezafungin is a useful addition to the treatments currently available for invasive candidiasis in adults, with potential benefits associated with less frequent administration compared with first-generation echinocandins.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Eraxis (anidulafungin) / RaQualia
PK/PD data, Review, Journal: Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation. (Pubmed Central) - Feb 1, 2025 The differentiated PK characteristics of rezafungin which enables once weekly dosing could reduce catheter overuse and provide a rapid transition to outpatient treatment for Candida infections in which azoles cannot be used, due to resistance or drug-drug interactions. Besides weekly dosing, other potential pharmacokinetic/pharmacodynamic advantages of rezafungin are its good penetration into anatomically challenging sites and a potentially reduced probability of local resistance promotion, making it an attractive option also for deep-seated infections that could warrant dedicated clinical investigation.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
Journal: New Perspectives on Antimicrobial Agents: Rezafungin. (Pubmed Central) - Jan 31, 2025 Herein, we review the most recent published data pertaining to rezafungin including anti-fungal activity, pharmacokinetics, and clinical data relating to the treatment of invasive candidiasis. Given its prolonged half-life allowing for once-weekly dosing, rezafungin has the potential as an anti-fungal prophylactic agent in high-risk patients, and studies to examine this potential role are ongoing.
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap
New P3 trial: Rezafungin Prophylaxis in Liver Transplant (clinicaltrials.gov) - Jan 14, 2025 P3, N=385, Not yet recruiting,
- |||||||||| Rezzayo (rezafungin for injection) / Cidara Therap, Mundipharma, Melinta Therap, Eraxis (anidulafungin) / RaQualia, Mycamine (micafungin) / Astellas
PK/PD data, Review, Journal: Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations. (Pubmed Central) - Dec 21, 2024 Numerous popPK models of echinocandins have been developed. However, an external validation of the suggested dosing regimens in conjunction with an analysis of population subgroups should be conducted before implementing a popPK model in clinical practice.
- |||||||||| Review, Journal: Proline Analogues in Drug Design: Current Trends and Future Prospects. (Pubmed Central) - Nov 28, 2024
Additionally, we discuss several intriguing cases where nonproline residues were replaced with proline analogues as a strategy to eliminate unwanted hydrogen bond donor sites. In conclusion, we present some suggestions for the future exploration of this promising class of molecular entities in drug discovery.
|